Profile data is unavailable for this security.
About the company
Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The Company operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.
- Revenue in DKK (TTM)55.69m
- Net income in DKK-1.19bn
- Incorporated1997
- Employees385.00
- LocationZealand Pharma A/SSydmarken 11SOEBORG 2860DenmarkDNK
- Phone+45 88773600
- Fax+45 88773898
- Websitehttps://www.zealandpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Basilea Pharmaceutica AG Allschwil | 1.67bn | 620.72m | 5.80bn | 164.00 | 9.74 | 8.13 | 9.14 | 3.48 | 5.59 | 5.59 | 15.05 | 6.70 | 0.9676 | 1.33 | 11.34 | 1,271,604.00 | 36.00 | 7.08 | 45.93 | 11.18 | 81.45 | 82.50 | 37.21 | 9.96 | 4.16 | 20.89 | 0.5422 | -- | 32.30 | 9.19 | 642.45 | -- | 34.71 | -- |
| Gubra A/S | -100.00bn | -100.00bn | 6.58bn | 236.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 29.63 | -- | 18.03 | -- | -- | -- |
| Kuros Biosciences AG | 553.16m | -27.40m | 9.00bn | 122.00 | -- | 21.22 | -- | 16.27 | -0.096 | -0.1102 | 2.37 | 1.38 | 0.9653 | 1.91 | 7.68 | 566,778.10 | -4.78 | -10.85 | -5.94 | -12.28 | 82.04 | 84.11 | -4.95 | -31.80 | 1.69 | -- | 0.0777 | -- | 129.67 | 101.59 | 62.67 | -- | 60.45 | -- |
| BioArctic AB | 1.00bn | 595.01m | 9.40bn | 116.00 | 18.85 | 8.80 | 13.91 | 9.39 | 10.20 | 10.20 | 17.16 | 21.85 | 0.931 | -- | -- | 14,180,610.00 | 55.34 | -2.87 | 60.55 | -3.22 | 97.61 | 86.59 | 59.44 | -12.41 | -- | -- | 0.0257 | -- | -58.22 | -1.80 | -177.24 | -- | 52.19 | -- |
| Evotec SE | 5.88bn | -1.54bn | 9.83bn | 4.77k | -- | 1.44 | -- | 1.67 | -1.17 | -1.17 | 4.44 | 5.14 | 0.3795 | 20.84 | 4.29 | 163,293.80 | -9.97 | -2.40 | -12.34 | -2.87 | 13.62 | 21.49 | -26.26 | -6.78 | 1.93 | -2.03 | 0.3442 | -- | 1.99 | 12.29 | -133.67 | -- | 32.89 | -- |
| Galapagos NV | 2.21bn | -1.34bn | 13.06bn | 704.00 | -- | 0.6369 | -- | 5.92 | -2.72 | -2.57 | 4.48 | 41.70 | 0.0705 | 0.7734 | 5.59 | 419,666.20 | -4.28 | -2.04 | -4.74 | -2.28 | 84.42 | -- | -60.70 | -27.56 | 7.86 | -- | 0.0039 | -- | 14.99 | -20.82 | 67.85 | -- | 12.44 | -- |
| Genus plc | 5.80bn | -34.54m | 13.80bn | 3.44k | -- | 3.09 | 40.56 | 2.38 | -0.0612 | -0.0612 | 10.16 | 7.82 | 0.6585 | -- | 6.11 | 195,289.30 | -0.6275 | 3.30 | -0.7199 | 3.87 | -- | -- | -0.953 | 4.98 | 1.33 | -- | 0.3656 | 62.72 | -3.03 | 6.48 | -76.28 | 0.2551 | -2.68 | 2.93 |
| BB BIOTECH AG | 553.30m | -3.40bn | 14.60bn | 86.00 | -- | 0.9268 | -- | 26.39 | -7.78 | -7.78 | 1.26 | 35.55 | 0.029 | -- | 5.61 | 804,244.20 | -17.82 | -1.24 | -19.26 | -1.35 | 94.80 | 97.19 | -615.24 | -39.47 | -- | 0.0771 | 0.00 | -- | 21,076.79 | -31.20 | 136.74 | -35.45 | -- | -11.94 |
| Zealand Pharma A/S | 55.69m | -1.19bn | 25.63bn | 385.00 | -- | 3.06 | -- | 460.13 | -17.30 | -17.30 | 0.811 | 117.53 | 0.0088 | 0.5409 | 0.7554 | 166,250.80 | -18.66 | -32.33 | -19.63 | -36.49 | 93.39 | 95.31 | -2,128.64 | -515.03 | 25.07 | -- | 0.0453 | -- | -81.71 | 8.69 | -53.30 | -- | -10.98 | -- |
| BACHEM HOLDING AG | 4.84bn | 961.95m | 34.83bn | 2.21k | 36.13 | 3.13 | 26.63 | 7.19 | 1.61 | 1.61 | 8.07 | 18.55 | 0.3357 | 1.07 | 2.91 | 274,245.10 | 6.67 | 8.26 | 7.61 | 9.44 | 30.16 | 31.55 | 19.87 | 20.06 | 1.33 | -- | 0.0002 | 52.54 | 4.84 | 14.05 | 7.50 | 17.29 | 56.91 | 7.21 |
| Qiagen NV | 12.89bn | 602.97m | 67.24bn | 5.70k | 119.05 | 3.07 | 36.46 | 5.22 | 0.3502 | 0.3502 | 7.87 | 13.57 | 0.3529 | 2.11 | 5.64 | 299,628.60 | 1.65 | 5.76 | 1.91 | 6.88 | 64.09 | 64.31 | 4.68 | 16.85 | 2.83 | -- | 0.2924 | -- | 0.6565 | 5.32 | -75.51 | -- | -9.03 | -- |
| Eurofins Scientific SE | 51.88bn | 4.74bn | 82.44bn | 62.70k | 18.58 | 2.12 | 8.60 | 1.59 | 3.26 | 1.81 | 35.74 | 28.58 | 0.6384 | 38.44 | 5.00 | 110,868.30 | 6.31 | 7.65 | 7.88 | 9.53 | 22.33 | 23.95 | 9.88 | 11.41 | 1.09 | 7.95 | 0.4014 | 23.54 | 6.70 | 8.78 | 22.85 | 15.36 | 4.45 | -- |
| Genmab A/S | 20.80bn | 7.30bn | 91.47bn | 2.64k | 12.54 | 2.65 | 11.75 | 4.40 | 113.70 | 113.70 | 323.83 | 538.06 | 0.5434 | 11.54 | 4.38 | 7,754,022.00 | 19.07 | 17.70 | 21.13 | 19.07 | 95.12 | -- | 35.10 | 35.77 | 5.32 | -- | 0.0263 | -- | 30.57 | 31.16 | 80.10 | 28.50 | 21.52 | -- |
Data as of Jul 18 2025. Currency figures normalised to Zealand Pharma A/S's reporting currency: Danish Krone DKK
32.41%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Capital International Ltd.as of 02 Jul 2025 | 4.36m | 6.15% |
| Fidelity Management & Research Co. LLCas of 31 May 2025 | 3.55m | 4.99% |
| J.O. Hambro Capital Management Ltd.as of 11 Jan 2024 | 3.13m | 4.40% |
| Polar Capital LLPas of 30 May 2025 | 2.42m | 3.41% |
| The Vanguard Group, Inc.as of 02 Jul 2025 | 2.40m | 3.37% |
| DWS Investments (UK) Ltd.as of 03 Jul 2025 | 1.80m | 2.53% |
| Capital Research & Management Co. (World Investors)as of 31 Mar 2025 | 1.48m | 2.09% |
| Schroder Investment Management Ltd.as of 31 May 2025 | 1.42m | 2.00% |
| Norges Bank Investment Managementas of 31 Dec 2024 | 1.26m | 1.78% |
| Handelsbanken Fonder ABas of 30 Jun 2025 | 1.20m | 1.69% |
More ▼
Data from 31 Dec 2024 - 30 Jun 2025Source: FactSet Research Systems Inc.
